Core Viewpoint - Insilico Medicine (03696) has announced a strategic collaboration with Kanghong Pharmaceutical for drug development, focusing on AI-powered innovative drug research in central nervous system and autoimmune disease areas [1] Group 1: Collaboration Details - The partnership will leverage Insilico's validated AI platform and drug development capabilities alongside Kanghong's experienced research team and deep understanding of disease areas [1] - The agreement stipulates the joint development of at least two research projects [1] Group 2: Financial Aspects - Insilico is expected to receive research funding support of up to tens of millions of Hong Kong dollars for each project [1]

本次获得FDA的FTD，将有助于加快依帕戈替尼在全球范围内的临床开发与监管审评进程。和誉医药将 持续推进该项目的国际化临床布局，致力于为全球HCC患者提供更加精准有效的创新治疗方案。 和誉-B(02256)发布公告，美国食品药品监督管理局(FDA)已授予和誉医药自主研发的高选择性小分子 FGFR4抑制剂依帕戈替尼(Irpagratinib/ABSK-011)快速通道资格认定(FTD)，用于治疗既往接受过免疫检 查点抑制剂(ICIs)和多靶点激酶抑制剂(mTKIs)治疗，且存在FGF19过表达的肝细胞癌(HCC)患者。 ...

Group 1 - The core viewpoint of the article is that Insilico Medicine (03696.HK) has entered into a strategic drug development collaboration with Kangji Medical (00867.HK) to leverage AI in innovative drug development for central nervous system and autoimmune diseases [1] - The collaboration will involve at least two research projects that will utilize Insilico's validated AI platform and drug development capabilities, combined with Kangji's experienced research team and deep understanding of disease areas [1] - Insilico is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project [1]

智通财经APP讯，和誉-B(02256)发布公告，美国食品药品监督管理局(FDA)已授予和誉医药自主研发的 高选择性小分子FGFR4抑制剂依帕戈替尼(Irpagratinib/ ABSK-011)快速通道资格认定(FTD)，用于治疗既 往接受过免疫检查点抑制剂(ICIs)和多靶点激酶抑制剂(mTKIs)治疗，且存在FGF19过表达的肝细胞癌 (HCC)患者。 本次获得FDA的FTD，将有助于加快依帕戈替尼在全球范围内的临床开发与监管审评进程。和誉医药将 持续推进该项目的国际化临床布局，致力于为全球HCC患者提供更加精准有效的创新治疗方案。 ...

美东时间周一，三大指数集体收涨，在科技股的带领下，纳指涨近1%，道指微涨，再创历史新高，标普500指数上涨0.5%，距离历史高点仅一步之遥。 （标普500指数日内走势，来源：TradingView） 截至收盘，道琼斯指数涨0.04%，报50,135.87点；标普500指数涨0.47%，报6,964.82点；纳斯达克指数涨0.90%，报23,238.67点。 英伟达和博通周一再次表现突出，分别上涨2.5%和3.3%，延续了前一交易日的涨势。另一家人工智能（AI）概念股甲骨文股价上涨9.6%。 此前一周早些时候市场曾遭遇明显抛售，那轮下跌主要由科技股、尤其是软件股领跌所引发。比特币也一度大幅下挫，随后略有回升，反映出投资者一度采 取避险姿态。 不过，美股市场在上周五大幅反弹，道指历史性地首次突破5万点。 CFRA Research首席投资策略师Sam Stovall表示："投资者在想，'好吧，我们刚刚经历了一次强劲反弹，这种势头能否持续？我现在进场，会不会只是被吸 引进去，结果又遭遇重挫，还是说这真的是又一次买入机会？'" 在谈到科技股相对于过去五年平均水平的远期市盈率时，Stovall表示："我们已经从溢价17 ...

据美国食品和药品监督管理局（FDA）称，丹麦制药公司诺和诺德为其口服减肥药投放的一则电视广告 涉及"虚假或误导性"宣传。 诺和诺德是司美格鲁肽（Semaglutide）的生产商，这款药物和礼来的替尔泊肽（Tirzepatide）均属于 GLP-1减肥药。 今年1月，口服版司美格鲁肽在美国获准上市，系全球首款进入市场的GLP-1类肥胖治疗口服药。诺和 诺德上周表示，目前已有超过17万名美国患者正在使用该药。 FDA要求诺和诺德立即采取行动纠正相关违规行为，其中可能包括停止所有含有误导性宣传内容的广告 投放。 诺和诺德周一发表声明确认已收到FDA的来信，并表示："我们高度重视所有监管方面的反馈，目前正 与FDA沟通，回应其对广告呈现方式所提出的关切。" 诺和诺德起诉Hims & Hers，寻求禁止仿制药并索赔 同样在周一，诺和诺德还对远程医疗公司Hims & Hers提起诉讼，要求法院禁止其大规模营销司美格鲁 肽口服药和注射剂的复方仿制版本，并寻求损害赔偿。 然而，FDA在2月5日致诺和诺德的一封信中指出，诺和诺德为这款药物投放的广告构成了"错误标示 （misbranding）"，因此其传播行为违反了联邦法律。 ...

Group 1 - The U.S. stock market opened lower, with the Dow Jones down 0.14%, while the Nasdaq rose by 0.11% and the S&P 500 increased by 0.18% [1] - Weight loss drug stocks saw a general increase, with Novo Nordisk rising over 6% and Eli Lilly up more than 2%. In contrast, Hims & Hers, facing a lawsuit for infringing on the patent of semaglutide, dropped 24% [1][3] - Novo Nordisk filed a lawsuit against Hims & Hers for allegedly misleading consumers about the clinical benefits and safety of its compounded semaglutide products, which are produced using unregulated raw materials [3] Group 2 - The FDA informed Novo Nordisk that the advertising for its weight loss drug Weeovy is either false or misleading [4] - Nvidia's stock rose by 3.31%, with a market capitalization increase of approximately $477.74 billion (around 3.31 trillion RMB) over two trading days [4] - AI application software stocks experienced a rebound, with Roblox rising over 9%, Applovin up more than 8%, and Unity Software increasing by nearly 8% [11]

Group 1 - Foreign institutions remain enthusiastic about A-shares, with 224 foreign institutions conducting 569 surveys of A-share listed companies as of February 9, 2026 [2][6] - Notable foreign institutions such as Morgan Stanley, BlackRock, Goldman Sachs, and Citigroup are involved in these surveys [2][6] - Goldman Sachs maintains a "overweight" rating on Chinese stocks, predicting a 20% increase in the China index and a 12% increase in the CSI 300 index [2][6] - UBS forecasts a significant rebound in the MSCI China index's earnings growth from 2.5% last year to 13.6% this year, primarily driven by technology stocks [2][6] - The top three companies attracting foreign interest are Huaming Equipment, Yingshi Innovation, and Huichuan Technology, with over 20 foreign institutions also researching companies like Aopt, Yihua, and Anji Technology [2][6] Group 2 - UBS Wealth Management's CIO office highlights the growth and profit potential of the Chinese market, driven by ongoing technological innovation and a favorable business environment [2][6] - The healthcare sector's international expansion, the rise of new consumption models, and the modernization of the power grid are expected to benefit industries such as healthcare, consumer goods, materials, and power equipment [2][6] Group 3 - In 2026, optimism for the Chinese stock market is maintained due to improving fundamentals and long-term growth drivers, which are expected to create a more sustainable structural growth cycle [3][7] - Key investment opportunities identified include industrial upgrades in electric vehicles, pharmaceuticals, and automation, with companies having strong R&D capabilities poised to meet market demands [3][7] - The trend of artificial intelligence is highlighted, with China emerging as a strong competitor in the global AI landscape, supported by a large internet user base, low energy costs, and abundant talent and data resources [3][7] - Changes in consumer preferences and demographic shifts are anticipated to lead to a significant transformation in the Chinese consumption market, with younger consumers increasingly spending on services and IP-related products [3][7]

TQB2102是集团自主研发的新一代HER2双表位双特异性抗体偶联药物(ADC)，通过三项核心技术创 新，实现疗效与安全性的优化平衡：1. 双表位靶向设计：抗体端采用非对称型结构设计，同时结合 HER2的ECD II/IV结构域，可显著提升对肿瘤细胞的选择性及药物内吞效率，从而增强抗肿瘤活性。2. 可裂解连接子：采用酶裂解型连接子，能够高效裂解释放毒素，并具备"旁观者效应"，清除周边异质性 肿瘤细胞，扩大杀伤范围。3. 优化的药物抗体比(DAR)：DAR值稳定控制在5.8-6.0，搭配拓扑异构酶I (Topo I)抑制剂毒素，在提升疗效的同时降低毒副作用。以上核心技术的结合，突破了传统HER2单抗及 单靶点ADC的局限，使TQB2102在HER2低表达肿瘤治疗中展现出显著潜力。 格隆汇2月10日丨中国生物制药(01177.HK)发布公告，集团自主研发的国家1类创新药TQB2102"HER2双 抗ADC"正在开展一项"评价注射用TQB2102对比研究者选择的化疗在HER2低表达复发╱转移性乳腺癌 中有效性和安全性的随机、开放、平行对照的III期临床试验(TQB2102-III-01)"，近期已完成全部受试者 入 ...

Core Viewpoint - The company is advancing its self-developed innovative drug TQB2102, a HER2 dual-targeted antibody-drug conjugate (ADC), through a Phase III clinical trial to evaluate its efficacy and safety in patients with HER2 low-expressing recurrent or metastatic breast cancer [1][2] Group 1: Clinical Trial and Drug Development - TQB2102 is undergoing a randomized, open-label, parallel-controlled Phase III clinical trial (TQB2102-III-01) to compare its effectiveness against chemotherapy in HER2 low-expressing breast cancer [1] - The drug incorporates three core technological innovations: dual-target design, cleavable linker, and optimized drug-antibody ratio (DAR), enhancing its antitumor activity and safety profile [1] Group 2: Clinical Results - At the 2025 ASCO annual meeting, the company reported promising results from a Phase Ib clinical study of TQB2102 in HER2 low-expressing advanced breast cancer, showing an overall objective response rate (ORR) of 53.4% among previously treated patients [2] - Notably, in the 7.5 mg/kg group, the ORR reached 58.3%, and 44.4% of patients who had previously progressed on ADC treatment achieved a response after TQB2102 therapy [2] - The safety profile indicated that grade 3 or higher treatment-related adverse events (TRAEs) included neutropenia (23.3%), leukopenia (20.6%), anemia (8.2%), and hypokalemia (6.9%), with overall tolerability being good [2] Group 3: Market Positioning - The company has established a comprehensive portfolio in breast cancer treatment, covering various molecular subtypes including HER2+, HER2 low-expressing, HR+/HER2-, and triple-negative breast cancer, aiming to provide new treatment options across all stages of disease management [2]